Want to see ENVB full AI Analyst Report?
ENVB Stock Chart & Stats
$3.72
-$0.12(-23.95%)
At close: 4:00 PM EST
$3.72
-$0.12(-23.95%)
Day’s Range― - ―
52-Week Range$1.26 - $17.63
Previous CloseN/A
Volume362.16K
Average Volume (3M)781.31K
Market Cap
$4.93M
Enterprise Value-$1.98
Total Cash (Recent Filing)$4.91M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-27.34
Shares Outstanding3,681,884
10 Day Avg. Volume899,153
30 Day Avg. Volume781,309
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.29
Price to Sales (P/S)0.00
P/FCF Ratio-0.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-315
Revenue Forecast (FY)$10.00M
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no recorded debt reduces fixed financial obligations and interest expense, giving management flexibility to prioritize R&D and clinical programs. Over a 2–6 month horizon, this lowers insolvency risk and preserves cash for development versus debt-laden peers, supporting operational continuity.
Improving Operating LossesThe material improvement in operating losses versus prior years suggests management is tightening cost structure or advancing programs more efficiently. Sustained improvement reduces near-term funding needs and increases the probability that existing resources extend clinical runway over coming months.
Governance And Incentive AlignmentFormalizing multi-year vesting and updating award agreements aligns executive and director incentives to long-term clinical and shareholder outcomes. Coupled with director elections and say-on-pay support, this strengthens governance and may improve strategic consistency across upcoming development milestones.
Bears Say
No Revenue, Negative Gross ProfitAbsence of product revenue and persistent negative gross profit mean the company remains pre-revenue and dependent on external financing. This structural lack of commercial cashflow keeps long-term viability tied to clinical success and fundraising, raising execution and financing risk over the medium term.
Persistent Cash BurnSustained negative operating and free cash flow indicates material ongoing funding needs. With cash burn accelerating versus the prior year, the company faces elevated dilution or financing pressure unless expenses fall or non-dilutive funding appears, constraining strategic optionality in 2–6 months.
Small Equity Base And Dilution RiskA modest equity cushion relative to recurring losses increases the likelihood of further equity issuance; recent ATM sales and a new prospectus confirm active dilution. Continued share issuance can erode existing ownership and signal recurring dependence on equity markets for runway.
Enveric Biosciences News
ENVB FAQ
What was Enveric Biosciences’s price range in the past 12 months?
Enveric Biosciences lowest stock price was $1.26 and its highest was $17.63 in the past 12 months.
What is Enveric Biosciences’s market cap?
Enveric Biosciences’s market cap is $4.93M.
When is Enveric Biosciences’s upcoming earnings report date?
Enveric Biosciences’s upcoming earnings report date is Aug 17, 2026 which is in 28 days.
How were Enveric Biosciences’s earnings last quarter?
Enveric Biosciences released its earnings results on May 15, 2026. The company reported -$1.082 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Enveric Biosciences overvalued?
According to Wall Street analysts Enveric Biosciences’s price is currently Overvalued.
Does Enveric Biosciences pay dividends?
Enveric Biosciences does not currently pay dividends.
What is Enveric Biosciences’s EPS estimate?
Enveric Biosciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enveric Biosciences have?
Enveric Biosciences has 3,681,884 shares outstanding.
What happened to Enveric Biosciences’s price movement after its last earnings report?
Enveric Biosciences reported an EPS of -$1.082 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.747%.
Which hedge fund is a major shareholder of Enveric Biosciences?
Currently, no hedge funds are holding shares in ENVB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enveric Biosciences
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.
Technical Analysis
Biodexa Pharmaceuticals
―
―
Indaptus Therapeutics
―
GT Biopharma
―
Artelo Biosciences
―
Ownership Overview
16.62% Insiders
0.22% Mutual Funds
0.46% Other Institutional Investors
81.30% Public Companies and
Individual Investors